-+ 0.00%
-+ 0.00%
-+ 0.00%
Evonik invests over CAD 150 million to expand lipid drug delivery production in Vancouver
Share
Listen to the news
Evonik invests over CAD 150 million to expand lipid drug delivery production in Vancouver
  • Evonik Industries AG to invest more than CAD 150 million in a new GMP plant for lipid-based drug delivery in Vancouver.
  • Project backed by up to CAD 68 million from Canada’s Strategic Response Fund.
  • New site to triple current capacity for advanced pharmaceutical products, strengthening quality assurance and microbiological testing.
  • Facility aimed at rising demand for lipid nanoparticle development, clinical drug supply, process scale-up toward commercial production.
  • Drug production scheduled to start by end-2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evonik Industries AG published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending